Peter Allen

About

Peter Allen is the David C. Sabiston, Jr. Distinguished Professor of Surgery at Duke University. He serves as a Professor of Surgery and the Chair of Surgery within the Duke Department of Surgery. Additionally, he holds the position of Vice President for Cancer Services and is a member of the Duke Cancer Institute. His professional focus includes surgical oncology, hepatopancreatobiliary surgery, and complex general surgical oncology. Dr. Allen is involved in pancreatic cancer research and oversees the Pancreatic Cancer Research Laboratory. His work emphasizes advancing surgical techniques and cancer treatment, contributing significantly to the field through leadership roles and research initiatives at Duke University.

Research topics

• Internal medicine
• Medicine
• Oncology
• General surgery
• Surgery
• Economics
• Statistics

Selected publications

• Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

  Hepatology · 2021 · 160 citations

  BACKGROUND AND AIM: Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown. APPROACH AND RESULTS: This bi-institutional study of patients with confirmed iCCA (n = 412) used targeted next-generation sequencing of primary tumors to define associations among genetic alterations, clinicopathological variables, and outcome. The most common oncogenic alterations were isocitrate dehydrogenase 1 (IDH1;…

  DOI

• Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms Reveals Divergent Indolent and Malignant States

  Clinical Cancer Research · 2025-02-19 · 8 citations

  articleOpen accessSenior author

  PURPOSE: Intraductal papillary mucinous neoplasms (IPMN) occur in 5% to 10% of the population, but only a small minority progress to pancreatic ductal adenocarcinoma (PDAC). The lack of accurate predictors of high-risk disease leads to both unnecessary operations for indolent neoplasms and missed diagnoses of PDAC. Digital spatial RNA profiling (DSP-RNA) provides an opportunity to define and associate transcriptomic states with cancer risk. EXPERIMENTAL DESIGN: We performed whole-transcriptome D…

  PublisherOA PDFDOI

• Multiplexed glycan immunofluorescence identification of pancreatic cancer cell subpopulations in both tumor and blood samples

  Science Advances · 2025-03-07 · 3 citations

  articleOpen access

  Pancreatic ductal adenocarcinoma (PDAC) tumor heterogeneity impedes the development of biomarker assays for early disease detection. We hypothesized that PDAC cell subpopulations could be identified by aberrant glycan signatures in both tumor tissue and blood samples. We used multiplexed glycan immunofluorescence to distinguish between PDAC and noncancer cell subpopulations within tumor tissue, and we developed hybrid glycan sandwich assays to determine whether the aberrant glycan signatures cou…

  PublisherDOI

• Development of Multiservice Machine Learning Models to Predict Postsurgical Length of Stay and Discharge Disposition at the Time of Case Posting

  Annals of Surgery Open · 2025-01-31 · 2 citations

  articleOpen accessCorresponding

  Objective: Develop machine learning (ML) models to predict postsurgical length of stay (LOS) and discharge disposition (DD) for multiple services with only the data available at the time of case posting. Background: Surgeries are scheduled largely based on operating room resource availability with little attention to downstream resource availability such as inpatient bed availability and the care needs after hospitalization. Predicting postsurgical LOS and DD at the time of case posting could su…

  PublisherDOI

• Preparing for the Inevitable: Early Comprehensive Genomic Profiling for Patients With Localized Pancreatic Ductal Adenocarcinoma

  JCO Oncology Practice · 2025-11-14 · 1 citations

  article

  PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease, even for patients diagnosed at a radiographically localized stage. Despite disease recurrence in most patients who undergo curative-intent therapy, national guidelines do not currently recommend comprehensive genomic profiling (CGP) until progression occurs following treatment. As the number of approved and investigational therapies expands for PDAC, ensuring access to early CGP data is critical for implementing molecula…

  PublisherDOI

Frequent coauthors

• Sabino Zani

  Duke Medical Center

  70 shared

• Michael E. Lidsky

  Duke Medical Center

  58 shared

• Dan G. Blazer

  Duke Medical Center

  50 shared

• Daniel P. Nussbaum

  Duke University

  41 shared

• Kevin N. Shah

  Duke University

  34 shared

• Demetrios Moris

  Duke University Hospital

  32 shared

• William R. Jarnagin

  Memorial Sloan Kettering Cancer Center

  30 shared

• Austin M. Eckhoff

  Duke University

  25 shared

Similar researchers at Duke University

• Darell Doty Bignerh-190
• Andrew Serghios Barbash-35
• Ryan M Antielh-26